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Multi-column continuous chromatography (MCC) is a scalable technology previ-
ously demonstrated to improve productivity and lower the cost of Protein A affinity 
chromatography versus the standard single column batch process. In this study we 
employed a lab-scale 8-column MCC process to compare the performance of three 
different Protein A adsorbents with high-titer human monoclonal IgG1 culture fluids. 
Productivities approaching 100 g mAb/L resin/h were achieved with 7.5 g/L titers. We 
then investigated another MCC process using hydroxyapatite (HA) for aggregate re-
moval and concurrent depletion of impurities from Protein A-purified mAb. Results in-
dicate that MCC-HA was capable of reducing aggregate and other impurity levels to 
meet FDA standards.
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 OctaveTM Chromatography System
• Performs SMBC, MCC and other continuous chromatography protocols
• Runs up to 8 columns, up to 8 pumps
• Patented valve block design
• Scalable from 12 ml/min to 300 ml/min flow rates; grams to kilograms per run
• Large scale GMP-compliant system under development
8 X 1-ml columns
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1. Feed  80% SBC at 0.5 min/column residence time*
2. Wash 10 CV 25 mM Na phosphate, 1 M NaCl, pH 6.7
3. Elute  5 CV 100 mM citrate, pH 3.0
4. Clean 4 CV 100 mM NaOH, 1 M NaCl
5. Equil  10 CV PBS
Sample [NaCl] mM
Monomer 
Yield (%)
Aggregate 
%
[HCP]  
log red.
[DNA] 
pg/mg
[Protein A] 
ppm
High Aggregate mAb
(19%)
---- N/A 19 1.8 0.4 0.1
750 91 4.9 2.7 <0.02 0.08
700 81 4.0 2.7 <0.02 0.06
Low Aggregate mAb
(2.4%)
---- N/A 2.4 1.8 0.3 0.1
700 78 1.2 2.7 <0.02 <0.05
600 76 1.1 2.8 <0.02 <0.05
500 70 0.9 2.7 <0.02 <0.05
* Residence time limited to 0.7 and 1.0 min/col for 5.0 and 7.5 g/L mAb, respectively, for  
  MabSelect SuRe due to limitation of linear flow velocity
Cell  culture harvest
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affinity chromatography
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diafiltration
Test MCC productivity
with high mAb titers
Apply MCC using mixed 
mode hydroxyapatite
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mCC ProCess
mCC ProteIn a CaPture
 MCC productivity of three different Protein A resins with  
mAb feed concentrations of 5.0 and 7.5 g/L
Hydroxyapatite (HA) is a hexagonal crystalline calcium phosphate matrix that inter-
acts with biomolecules via calcium ion affinity, cation exchange, and hydrogen bonding.  
CaPureTM-HA (Tosoh Bioscience) is a spherical form of HA with high capacity and flow  
properties. HA has been shown to bind IgG aggregates more tightly than monomers 
(Gagnon 2009). We investigated using this adsorbent in an MCC process for removal 
of aggregates and other impurities from Protein A-purified mAb.
mIxed mode hydroxyaPatIte
mCC-ha method develoPment
1.  Determine [PO4] and [NaCl] elution conditions by single column gradients
  a.  Run Na phosphate (pH 6.8) gradient at 50 mM NaCl: mAb eluted at 60 mM PO4
  b.  Run NaCl gradient at 5, 10, and 20 mM PO4: at 10 mM PO4 mAb eluted at  
       600 mM NaCl and contained 99.5% monomer; aggregate remained on column.
2.  Determine binding capacity under loading conditions (10 mM PO4, 50 mM NaCl, pH 6.8)
  DBC @ 10% breakthrough = 31 mg/ml at 1 min residence time
              = 47 mg/ml at 3 min residence time
3.  Run MCC process and optimize [NaCl] elution for monomer yield and purity
We used two preparations of Protein A-purified mAb containing different amounts 
of aggregate as samples (Feed) for MCC-HA runs. The High Aggregate (19%) sample 
was prepared by using glycine pH 2.3 for elution in the MCC-PAC process, and the 
Low Aggregate (2.4%) sample resulted from using pH 2.6 for elution. In both cases 
the MCC-PAC sample was incubated for 30 min at low pH, then adjusted to pH 6.8 
with 1 M Tris-Cl, pH 9 before use as feed for the MCC-HA runs.
Results show that the continuous HA process reduced the aggregate content 4-5 
fold for the High Aggregate sample and 2-3 fold for the Low Aggregate sample, with 
monomer recoveries ranging from 70-90%. HCP, DNA and Protein A concentrations 
were reduced to very low levels.
Protocol
1. Feed  20 mg/ml PAC mAb at 1 min/column residence time*
2. Wash 8 CV 10 mM NaPO4, pH 6.8, 50 mM NaCl
3. Elute  7 CV 10 mM NaPO4, pH 6.8,  500-750 mM NaCl
4. Clean 5 CV 250 mM NaPO4, 250 mM NaOH
5. Equil  10 CV 10 mM NaPO4, pH 6.8, 50 mM NaCl
mCC-ha results
multimer 
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Low Aggregate Product
Gagnon, P. (2009) Monoclonal antibody purification with hydroxyapatite. New Biotechnol. 25, 287.
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